Answers are grounded in this paper and cite their sources.
Exploratory study shows niacinamide maintains macular stability in primary open-angle glaucoma, indicating short-term safety.
When inter-eye correlation is appropriately accounted for, six months of niacinamide supplementation in POAG is associated with overall functional, structural, and electrophysiological stability, without evidence of clinically meaningful improvement or progression. These findings support short-term safety and highlight the importance of clustered analytical approaches and macular-centered biomarkers in future glaucoma neuroprotection trials.
No takes yet. Share an insight, caveat, or question.
Nicola et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: